Disclaimer - Please note that the insurance accepted list may not be complete. Prior to scheduling an appointment, please contact the doctors' office to verify their participation in your plan.
| Specialty | Radiation Oncology |
|---|---|
| Clinical Interests | Prostate Cancer |
| Radiation Therapy | |
| Radiation Oncology | |
| Languages | English |
| French | |
| Chinese (Mandarin) | |
| Spanish | |
| Hebrew | |
| Afrikaans | |
| Gender | Male |
| richard.stock@mountsinai.org | |
| Education and Training | MD, Mount Sinai School of Medicine |
| Residency, Internal Medicine, Beth Israel Medical Center | |
| Residency, Radiation Oncology, Memorial Sloan-Kettering |
| Education and Training | MD, Mount Sinai School of Medicine |
|---|---|
| Residency, Internal Medicine, Beth Israel Medical Center | |
| Residency, Radiation Oncology, Memorial Sloan-Kettering | |
| Board Certification | Radiation Oncology |
| Specialty | Radiation Oncology |
|---|---|
| Clinical Interests | Prostate Cancer |
| Radiation Therapy | |
| Radiation Oncology | |
| Languages | English |
| French | |
| Chinese (Mandarin) | |
| Spanish | |
| Hebrew | |
| Afrikaans | |
| Board Certification | Radiation Oncology |
Stock RG, Stone NN. The effect of brachytherapy, external beam irradiation, and hormonal therapy on prostate volume. J Urol ;.
Schiff JD, Stock R, Cesaretti J, Bar Charma N. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU 2006; 98: 1255.
Stock RG, Stone NN. Long-term urinary, sexual and rectal morbidity in patients treated with I-125 prostate brachytherapy followed for a minimum of 5 years. Urology;.
Ho A, Burri R, Stock RG, Stone NN, Cesaretti JA. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined Pd-103 implantation and external beam radiation for T3c prostate cancer. Brachytherapy 2007; 6(1): 38-43.
Zagar TM, Stone NN, Cesaretti JA, Stock RG. Assessment of post-brachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy 2007; 6(1): 26-33.
Lehrer S, Stock RG, Stone NN, Cesaretti J. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and increased pre-implant urinary symptoms. BJU Int 2006; 98(5): 979-981.
Stock RG, Stone NN, Cesaretti JA, Ho A. Changing the patterns of failure for high risk prostate cancer by optimizing local control. Int J Radiat Oncol Biol Phys 2006; 66(2): 389-394.
Peters C, Stock RG, Stone NN, Cesaretti JA. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2006; 66(2): 424-429.
Ferrari AC, Mandeli J, Kurek R, Mulligan E, Mcgregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M, Hall S, Renneberg H, Livak KJ, Gallagher RE, Stone NN. Molecular load of pathologically-occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 2006; 24(19): 3081-3088.
Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Rosenstein BS, Atencio DP, Green S, Formenti S, Stock RG, Cesaretti JA. ATM sequence variants and risk of radiation induced subcutaneous fibrosis after post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006; 64(3): 776-783.
Discover how The Mount Sinai Medical Center can offer you the most advanced and compassionate inpatient and outpatient care.
The Mount Sinai Medical Center is home to an extensive array of top-notch research centers and laboratories, where scientists and researchers work to translate the rapid advances in basic science into the innovative patient care for which we are known.
Participating in Mount Sinai’s clinical trials allows you to take advantage of innovative treatments as we work together to advance the future of medicine.
